TAVR utilization increased markedly from 2008 to 2020, with patients exhibiting fewer comorbidities over time (e.g., heart failure decreased from 40.5% to 25.2%) while age remained stable.
Cohort (n=6,097)
Yes
How have the utilization rates and patient characteristics for TAVR changed over time between 2008 and 2020?
TAVR utilization has expanded significantly over time to include patients with fewer comorbidities, though it remains predominantly utilized in older populations.
AIM: To investigate trends in the utilization of transcatheter aortic valve replacement (TAVR) and changes in the characteristics of patients undergoing first-time TAVR. METHODS: Using Danish nationwide registers, we included all patients undergoing TAVR between 2008 and 2020. To compare patient characteristics, the study population was stratified according to calendar year of procedure: 2008-2010, 2011-2013, 2014-2016, and 2017-2020. RESULTS: We identified 6,097 patients undergoing TAVR with year-by-year increases in TAVR penetration rate. Over time, the age of the patients remained stable (2008-2010: median age 82 year interquartile range (IQR): 77-86 vs 2017-2020: median age 81 years IQR: 77-85). Moreover, there was an increase in male patients (2008-2010: 49.9% vs 2017-2020: 57.4%) and patients with diabetes (2008-2010: 14.2% vs 2017-2020: 19.2%). Conversely, a history of stroke (2008-2010: 15.8% vs 2017-2020: 13.1%), previous myocardial infarction (2008-2010: 22.4% vs 2017-2020: 10.0%), heart failure (2008-2010: 40.5% vs 2017-2020: 25.2%), and peripheral artery disease (2008-2010: 14.8% vs 2017-2020: 10.4) decreased among patients. CONCLUSIONS: TAVR utilization increased markedly in the years 2008-2020. Patients undergoing TAVR had less comorbidity over time while age remained stable. Thus, despite expanding to patients at lower surgical risk, TAVR is still offered mainly to older patients.
Strange et al. (Mon,) conducted a cohort in Aortic valve disease requiring TAVR (n=6,097). Transcatheter aortic valve replacement (TAVR) vs. Calendar year cohorts (2008-2010 vs 2017-2020) was evaluated on Trends in utilization and patient characteristics. TAVR utilization increased markedly from 2008 to 2020, with patients exhibiting fewer comorbidities over time (e.g., heart failure decreased from 40.5% to 25.2%) while age remained stable.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: